David Jacoboff, MD
Interventional Cardiology · Roswell, GANPI 1215957030
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $61,200 of the $64,199 with a category attached, or 95.3%. Edwards Lifesciences accounts for 95.4% of it on its own, with 31 other manufacturers making up the rest. Reporting peaked in 2022 at $31,082 and has fallen 98.8% since, to $360 in 2025.
Across 151 payments — averaging $425.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$61K
- Johnson & Johnson$371
- Novartis$345
- Boehringer Ingelheim$316
- Amgen$300
- Pfizer$274
- plus $1K from 26 others
What the payments were for
- Consulting fees$61,20095%
- Food & beverage$2,9995%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 3 | $61,227 |
| Johnson & Johnson | 21 | $371 |
| Novartis | 17 | $345 |
| Boehringer Ingelheim | 15 | $316 |
| Amgen | 16 | $300 |
| Pfizer | 15 | $274 |
| Merck | 9 | $171 |
| Boston Scientific | 6 | $140 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 6 | $121 |
| Heartflow, Inc. | 4 | $107 |
| Abbott | 4 | $89 |
| Sanofi-aventis U.S. LLC | 4 | $87 |
| Altathera Pharmaceuticals LLC | 1 | $80 |
| Medtronic(2 entities) | 3 | $76 |
| AstraZeneca | 3 | $54 |
| E.r. Squibb & Sons, L.L.C. | 3 | $49 |
| Esperion Therapeutics, Inc. | 2 | $41 |
| Actelion Pharmaceuticals US, Inc. | 2 | $40 |
| ZOLL Circulation Inc | 1 | $31 |
| Cardinal Health 200 LLC | 2 | $30 |
| Shockwave Medical, Inc | 1 | $26 |
| Amarin Pharma, Inc. | 2 | $26 |
| Abiomed | 1 | $25 |
| Daiichi Sankyo Inc. | 1 | $23 |
| Cardiovascular Systems Inc. | 1 | $22 |
| Bardy Diagnostics, Inc. | 2 | $20 |
| Siemens Medical Solutions USA, Inc. | 1 | $20 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $20 |
| United Therapeutics Corporation | 1 | $19 |
| Cardiva Medical, Inc. | 1 | $18 |
| Cvrx, Inc. | 1 | $18 |
| GSK | 1 | $17 |
How this compares
$64,199 in reported general payments places this provider in the 85th percentile of 218 interventional cardiology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 423 | $449,189 |
| JardianceEmpagliflozin | 170 | $147,593 |
| BrilintaTicagrelor | 116 | $93,710 |
| EntrestoSacubitril/Valsartan | 77 | $72,132 |
| XareltoRivaroxaban | 32 | $41,820 |
| FarxigaDapagliflozin Propanediol | 14 | $20,206 |
| Repatha SureclickEvolocumab | 14 | $13,183 |
| Atorvastatin Calcium | 487 | $4,385 |
| Metoprolol Succinate | 349 | $4,170 |
| Rosuvastatin Calcium | 247 | $3,755 |
| Ranolazine ErRanolazine | 31 | $2,950 |
| Carvedilol | 357 | $2,870 |
| Losartan Potassium | 212 | $2,525 |
| Ezetimibe | 78 | $1,710 |
| Hydralazine Hcl | 84 | $1,510 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $274 | $449,189423 claims |
| Boehringer IngelheimJardiance | $316 | $147,593170 claims |
| AstraZenecaBrilinta, Farxiga | $54 | $113,916130 claims |
| NovartisEntresto | $345 | $72,13277 claims |
| Johnson & JohnsonXarelto | $371 | $41,82032 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 218 interventional cardiology providers in Georgia.
Other interventional cardiology in Roswell
- William NicholsonAtlanta$1000K
- David KandzariAtlanta$982K
- Pradeep YadavAtlanta$656K
- Salvatore ManninoMarietta$275K
- Megan CoylewrightCalhoun$271K
- Paul GuichardMarietta$260K
- Adam GreenbaumAtlanta$238K
- Wissam JaberAtlanta$222K
- Mudassar AhmedGainesville$193K
- Katherine KunkelAtlanta$189K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.